Literature DB >> 17383993

Effects of intravitreal triamcinolone acetonide injection with and without preservative.

Mauricio Maia1, Michel Eid Farah, Rubens N Belfort, Fernando Marcondes Penha, Acácio A S Lima Filho, Fabio Bom Aggio, Rubens Belfort.   

Abstract

AIMS: To evaluate the effects of intravitreal injection of preservative-free triamcinolone acetonide (PFTA) and TA containing preservative (KE).
METHODS: A retrospective review was conducted of 646 intravitreal 4 mg/0.1 ml steroid injections in 471 eyes. A total of 577 intravitreal injections of PFTA and 69 injections of KE were administered in non-randomised eyes. No supernatant removal from KE was performed. Non-infectious endophthalmitis was defined as pseudohypopyon/hypopyon with or without an inflammatory reaction that regressed after steroid eye drop instillation. Ocular hypertension was defined as more than 23 mm Hg with Goldman applanation tonometry. Patients were followed and examined 1, 7 and 28 days, and 3, 4, 6 and 12 months after injection and annually thereafter. Statistical analysis was performed using Fisher's exact test and Chi(2) test. p Values <0.05 were considered significant.
RESULTS: Both groups did not differ in demographics (p>0.05). Follow-up ranged from 6 to 57 months (mean 13, SD 7.5). Ocular hypertension was present in 127 eyes (20%), but both groups did not differ significantly (p = 0.167). Four eyes (3.15%) required trabeculectomy. Non-infectious endophthalmitis developed in 12 eyes (1.9%) and varied significantly in both groups (p = 0.005). One eye developed bacterial endophthalmitis (0.15%).
CONCLUSIONS: Non-infectious endophthalmitis was observed significantly more often after KE injections (7.3%) than after PFTA injections (1.2%) (p<0.05). An inflammatory reaction was more clinically relevant in the KE group than in the PFTA group.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17383993      PMCID: PMC1954894          DOI: 10.1136/bjo.2007.115386

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  17 in total

1.  Endophthalmitis after intravitreal injection of triamcinolone acetonide.

Authors:  Jost B Jonas; Ingrid Kreissig; Robert F Degenring
Journal:  Arch Ophthalmol       Date:  2003-11

2.  Retinal complications of intravitreal injections of triamcinolone acetonide.

Authors:  Jost B Jonas; Ingrid Kreissig; Robert F Degenring
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-12-16       Impact factor: 3.117

Review 3.  Evolving guidelines for intravitreous injections.

Authors:  Lloyd P Aiello; Alexander J Brucker; Stanley Chang; Emmett T Cunningham; Donald J D'Amico; Harry W Flynn; Lisa R Grillone; Steve Hutcherson; Jeffrey M Liebmann; Terrence P O'Brien; Ingrid U Scott; Richard F Spaide; Christopher Ta; Michael T Trese
Journal:  Retina       Date:  2004-10       Impact factor: 4.256

4.  Triamcinolone-assisted internal limiting membrane peeling during idiopathic macular hole surgery.

Authors:  Naoichi Horio; Masayuki Horiguchi; Naoki Yamamoto
Journal:  Arch Ophthalmol       Date:  2005-01

5.  Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations.

Authors:  T Hida; D Chandler; J E Arena; R Machemer
Journal:  Am J Ophthalmol       Date:  1986-02-15       Impact factor: 5.258

6.  Bacterial endophthalmitis. Treatment with intraocular injection of gentamicin and dexamethasone.

Authors:  G A Peyman; R Herbst
Journal:  Arch Ophthalmol       Date:  1974-05

7.  Visual outcomes following the use of intravitreal steroids in the treatment of postoperative endophthalmitis.

Authors:  G K Shah; J D Stein; S Sharma; A Sivalingam; W E Benson; C D Regillo; G C Brown; W Tasman
Journal:  Ophthalmology       Date:  2000-03       Impact factor: 12.079

8.  Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial.

Authors:  Mark C Gillies; Judy M Simpson; Frank A Billson; Wei Luo; Philip Penfold; William Chua; Paul Mitchell; Meidong Zhu; Alex B L Hunyor
Journal:  Arch Ophthalmol       Date:  2004-03

9.  Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection.

Authors:  Mark L Nelson; Matthew T S Tennant; Arunan Sivalingam; Carl D Regillo; Jonathan B Belmont; Adam Martidis
Journal:  Retina       Date:  2003-10       Impact factor: 4.256

10.  Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion.

Authors:  Jost B Jonas; Ingrid Kreissig; Robert F Degenring
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-08-13       Impact factor: 3.117

View more
  18 in total

1.  Steroid differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American Ophthalmological Society thesis).

Authors:  Baruch D Kuppermann; Leandro Cabral Zacharias; M Cristina Kenney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

2.  Intravitreal crystalline drug delivery for intraocular proliferation diseases.

Authors:  Lingyun Cheng; Karl Hostetler; Nadya Valiaeva; Ajay Tammewar; William R Freeman; James Beadle; Dirk-Uwe Bartsch; Kathy Aldern; Iryna Falkenstein
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-20       Impact factor: 4.799

3.  Purified triamcinolone acetonide as antifibrotic adjunct in glaucoma filtering surgery.

Authors:  Barend Frits Theodorus Hogewind; Benjamin Pijl; Carel Benedict Hoyng; Thomas Theelen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-09-29       Impact factor: 3.117

4.  Associated factors and treatment outcome of presumed noninfectious endophthalmitis occurring after intravitreal triamcinolone acetonide injection.

Authors:  Seong Joon Ahn; Tae Wan Kim; Jeeyun Ahn; Jang Won Huh; Hyeong Gon Yu; Hum Chung
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-07-22       Impact factor: 3.117

5.  Prophylactic antibiotic use after intravitreal injection: effect on endophthalmitis rate.

Authors:  Shabari S Bhatt; Kimberly E Stepien; Komal Joshi
Journal:  Retina       Date:  2011-11       Impact factor: 4.256

6.  Safety of intravitreal triamcinolone acetonide: an electrophysiologic and histopathological study in rabbits.

Authors:  Laila Hassan M El-Shazly; Amal Ahmad El-Gohary; Ghada Ghanem El-Hossary
Journal:  Int J Ophthalmol       Date:  2013-12-18       Impact factor: 1.779

7.  Comparisons of cone electroretinograms after indocyanine green-, brilliant blue G-, or triamcinolone acetonide-assisted macular hole surgery.

Authors:  Shigeki Machida; Yoshiharu Toba; Tomoharu Nishimura; Takayuki Ohzeki; Ken-ichi Murai; Daijiro Kurosaka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-03-02       Impact factor: 3.117

8.  Intravitreal triamcinolone for intraocular inflammation and associated macular edema.

Authors:  Steven M Couch; Sophie J Bakri
Journal:  Clin Ophthalmol       Date:  2009-06-02

9.  The effects of intravitreal triamcinolone acetonide in diabetic macular edema refractory to anti-VEGF treatment.

Authors:  In Hwan Hong; Wonseok Choi; Jae Ryong Han
Journal:  Jpn J Ophthalmol       Date:  2020-01-03       Impact factor: 2.447

10.  Vitreomacular traction syndrome.

Authors:  Juliana Bottós; Javier Elizalde; J Fernando Arevalo; Eduardo B Rodrigues; Maurício Maia
Journal:  J Ophthalmic Vis Res       Date:  2012-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.